Kimberly Noonan, PhD, MPH WindMIL Therapeutics/Nacelle Bio

Kimberly Noonan, PhD  is a scientific co-founder of marrow infiltrating lymphocyte (MIL) technology. Dr. Noonan, along with Ivan Borrello, MD have pioneered the use of MILs cell therapy. This therapy is showing promise for patients with multiple myeloma, but their research indicates that this personalized cell therapy would be beneficial in treating a variety of blood and bone marrow cancers as well as solid tumors. Dr. Noonan received her BS in Microbiology and PhD in Immunology from the University of Pittsburgh. She also holds an MPH from Johns Hopkins University. Dr. Noonan is published author on many peer-reviewed papers, review articles and book chapters and holds many patents. She joined the faculty of Johns Hopkins University in 2004. Along with being the founder, EVP and CSO and current CEO of  WindMIL Therapeutics, Dr. Noonan has also founded two other biopharma startups in the cancer vaccine and bispecific spaces as well as two in the cell manufacturing space. She has served as an consulting advisor to several mid to large biopharma companies. Dr. Noonan currently serves as the CEO of WindMIL Therapeutics, CSO of Nacelle Bio and is a consultant for several other groups in the cell and gene therapy space.